Skip to main content
Top
Published in: Clinical and Molecular Allergy 1/2011

Open Access 01-12-2011 | Case Report

Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab

Authors: Michael C Saavedra, Sanjiv Sur

Published in: Clinical and Molecular Allergy | Issue 1/2011

Login to get access

Abstract

Chronic idiopathic urticaria is a condition that is often controllable with antihistamine therapy. However, some patients have disease burden that is difficult to manage, non-responsive to antihistamines and often requires immunosuppressive medications such as corticosteroids or cyclosporine. We present here a study that demonstrates the effectiveness of omalizumab in treating this condition and the temporal relationship between improvement and down regulation of the high affinity IgE receptor (FcεRI). For this, blood samples were obtained from a symptomatic patient before each treatment and processed for flow cytometric analysis of FcεRI levels on the surface of blood basophils. Down regulation of FcεRI was observed in association with significant clinical improvement and discontinuation of immunosuppressive medications.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004, 114: 465-74. 10.1016/j.jaci.2004.02.049CrossRefPubMed Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004, 114: 465-74. 10.1016/j.jaci.2004.02.049CrossRefPubMed
3.
go back to reference Cebeci F, Tanrikut A, Topcu E, Onsun N, Kurtulmus N, Uras AR: Association between urticaria and thyroid autoimmunity. Eur J Dermatol. 2006, 16 (4): 402-5.PubMed Cebeci F, Tanrikut A, Topcu E, Onsun N, Kurtulmus N, Uras AR: Association between urticaria and thyroid autoimmunity. Eur J Dermatol. 2006, 16 (4): 402-5.PubMed
4.
go back to reference Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001, 108: 184-190. 10.1067/mai.2001.117880CrossRefPubMed Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001, 108: 184-190. 10.1067/mai.2001.117880CrossRefPubMed
5.
go back to reference Spector SL, Tan RA: Effects of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007, 99: 190-3. 10.1016/S1081-1206(10)60644-8CrossRefPubMed Spector SL, Tan RA: Effects of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007, 99: 190-3. 10.1016/S1081-1206(10)60644-8CrossRefPubMed
6.
go back to reference Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK: Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008, 122: 569-73. 10.1016/j.jaci.2008.07.006CrossRefPubMed Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK: Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008, 122: 569-73. 10.1016/j.jaci.2008.07.006CrossRefPubMed
7.
go back to reference Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB: Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol. 2004, 113: 297-302. 10.1016/j.jaci.2003.11.044CrossRefPubMed Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB: Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol. 2004, 113: 297-302. 10.1016/j.jaci.2003.11.044CrossRefPubMed
8.
go back to reference MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti- IgE antibody. J Immunol. 1997, 158: 1438-45.PubMed MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti- IgE antibody. J Immunol. 1997, 158: 1438-45.PubMed
9.
go back to reference Beck LA, Marcotte GV, MacGlashan DW Jr, Togias A, Saini S: Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol. 2004, 114: 527-30. 10.1016/j.jaci.2004.06.032CrossRefPubMed Beck LA, Marcotte GV, MacGlashan DW Jr, Togias A, Saini S: Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol. 2004, 114: 527-30. 10.1016/j.jaci.2004.06.032CrossRefPubMed
10.
go back to reference Galli SJ, Kawakami T: Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol. 2002, 2: 773-86. 10.1038/nri914CrossRefPubMed Galli SJ, Kawakami T: Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol. 2002, 2: 773-86. 10.1038/nri914CrossRefPubMed
Metadata
Title
Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab
Authors
Michael C Saavedra
Sanjiv Sur
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Clinical and Molecular Allergy / Issue 1/2011
Electronic ISSN: 1476-7961
DOI
https://doi.org/10.1186/1476-7961-9-2

Other articles of this Issue 1/2011

Clinical and Molecular Allergy 1/2011 Go to the issue